Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia

This is a prospective phase II clinical study to be conducted at the Medical College of Wisconsin. After meeting the study criteria and enrollment, patients will be treated with Cladribine

cytarabine
mitoxantrone
colony stimulating factor
ejection fraction
secondary acute myeloid leukemia
  • 60 views
  • 01 May, 2022
  • 1 location
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

chemotherapy, such as cladribine, idarubicin, cytarabine, and gemtuzumab ozogamicin, in participants with blood cancers.

cytarabine
myeloid leukemia
cancer chemotherapy
blast crisis
hematopoietic growth factors
  • 26 views
  • 23 Mar, 2022
  • 1 location
CVA Regimen Bridging to HSCT for R/R AL

leukemic cells before HSCT, there is still no consensus that which regimen is optimal. This study is to investigate the curative efficacy and safety of bridging CVA (cladribine combined with venetoclax and

  • 0 views
  • 03 May, 2022
  • 1 location
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" [cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)] in

graft versus host disease
cytarabine
colony stimulating factor
flow cytometry
gemtuzumab ozogamicin
  • 8 views
  • 15 Mar, 2022
  • 1 location
A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol

therapies for RO+ patients with recurrent disease. During the time of this study, cladribine was unavailable. Second-line therapy for non-responders or patients with disease reactivation was individualized

  • 0 views
  • 06 Mar, 2021
  • 1 location
CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

This phase I trial studies the best dose of total body irradiation when given with CLAG-M chemotherapy reduced-intensity conditioning regimen before stem cell transplant in treating patients with acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Giving …

  • 0 views
  • 08 Apr, 2022
  • 1 location
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

In this prospective study, 30 newly untreated elderly patients with acute myeloid leukemia(AML) who were not suitable for standard chemotherapy were enrolled to observe the efficacy and side effects of venetoclax (VEN) combined with azacytidine (AZA) and chemotherapy in newly treated elderly patients with AML. Overall survival (OS), complete remission …

cytarabine
azacitidine
venetoclax
cladribine
idarubicin
  • 0 views
  • 09 May, 2022
  • 1 location
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis

The success of the U.S. vaccination program against SARS-Cov-2 is shown by a dramatic drop in infection rates, hospitalizations and deaths.However, it appears that many persons who take medications that chronically suppress the immune system do not produce neutralizing antibodies to COVID-19 proteins in response to vaccination. This group includes …

Accepts healthy volunteers
  • 0 views
  • 22 Mar, 2022
  • 1 location
Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

The purpose of this study is to assess the efficacy of autologous PBSCT versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) for inflammatory MS failing alternate approved therapy. Disease progression, defined as a 1-point increase in the Expanded Disability Status scale (EDSS) on …

natalizumab
mitoxantrone
corticosteroids
avonex
fingolimod
  • 120 views
  • 08 Nov, 2020
  • 1 location
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction …

refractory acute myeloid leukemia (aml)
ara-c
azacitidine
neoadjuvant therapy
cytarabine
  • 71 views
  • 16 Feb, 2022
  • 35 locations